$RPTX
Repare Therapeutics Inc.

2023 Q4 Form 10-Q Financial Statement

#000095017023061521 Filed on November 09, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3
Revenue $13.05M $2.200M
YoY Change -28.31% -98.05%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $8.648M $7.900M
YoY Change 8.93% -0.05%
% of Gross Profit
Research & Development $35.27M $32.71M
YoY Change 17.98% 4.7%
% of Gross Profit
Depreciation & Amortization $506.0K $500.0K
YoY Change 11.21% 3.31%
% of Gross Profit
Operating Expenses $43.91M $40.58M
YoY Change 16.08% 3.66%
Operating Profit -$38.42M
YoY Change -152.34%
Interest Expense $3.073M $3.300M
YoY Change 2.81% 53.27%
% of Operating Profit
Other Income/Expense, Net -$46.00K $3.240M
YoY Change -453.85% 53.12%
Pretax Income -$27.84M -$35.18M
YoY Change 67.41% -146.58%
Income Tax $190.0K -$16.30M
% Of Pretax Income
Net Earnings -$28.03M -$18.88M
YoY Change -11.46% -125.02%
Net Earnings / Revenue -214.84% -858.14%
Basic Earnings Per Share -$0.45
Diluted Earnings Per Share -$0.67 -$0.45
COMMON SHARES
Basic Shares Outstanding 42.13M 42.09M
Diluted Shares Outstanding 42.10M

Balance Sheet

Concept 2023 Q4 2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $223.6M $250.1M
YoY Change -34.98% 61.16%
Cash & Equivalents $111.3M $107.4M
Short-Term Investments $112.4M $142.7M
Other Short-Term Assets $4.749M $5.600M
YoY Change -16.9% -0.62%
Inventory
Prepaid Expenses $4.749M $5.551M
Receivables
Other Receivables $4.499M $3.731M
Total Short-Term Assets $243.7M $275.1M
YoY Change -31.16% -29.57%
LONG-TERM ASSETS
Property, Plant & Equipment $4.215M $4.722M
YoY Change -0.31% 0.83%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $396.0K $397.0K
YoY Change -20.32% -20.12%
Total Long-Term Assets $10.21M $11.31M
YoY Change 1.16% -39.04%
TOTAL ASSETS
Total Short-Term Assets $243.7M $275.1M
Total Long-Term Assets $10.21M $11.31M
Total Assets $253.9M $286.4M
YoY Change -30.26% -30.0%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.400M $5.438M
YoY Change 420.61% -41.81%
Accrued Expenses $26.26M $23.00M
YoY Change 11.54% 31.53%
Deferred Revenue $10.22M $20.47M
YoY Change -80.75% -41.15%
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $39.08M $48.97M
YoY Change -50.29% -20.85%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $2.740M $4.100M
YoY Change -53.86% -90.12%
Total Long-Term Liabilities $2.740M $4.100M
YoY Change -53.86% -90.12%
TOTAL LIABILITIES
Total Short-Term Liabilities $39.08M $48.97M
Total Long-Term Liabilities $2.740M $4.100M
Total Liabilities $41.82M $53.04M
YoY Change -50.54% -48.7%
SHAREHOLDERS EQUITY
Retained Earnings -$333.1M -$305.1M
YoY Change 39.2% 46.92%
Common Stock $545.2M $538.7M
YoY Change 4.99% 4.81%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $212.1M $233.4M
YoY Change
Total Liabilities & Shareholders Equity $253.9M $286.4M
YoY Change -30.26% -30.0%

Cashflow Statement

Concept 2023 Q4 2023 Q3
OPERATING ACTIVITIES
Net Income -$28.03M -$18.88M
YoY Change -11.46% -125.02%
Depreciation, Depletion And Amortization $506.0K $500.0K
YoY Change 11.21% 3.31%
Cash From Operating Activities -$28.16M -$32.87M
YoY Change -5.0% -137.29%
INVESTING ACTIVITIES
Capital Expenditures $398.0K $0.00
YoY Change -123.14% -100.0%
Acquisitions
YoY Change
Other Investing Activities $32.28M $24.50M
YoY Change -0.19% -111.74%
Cash From Investing Activities $31.88M $24.50M
YoY Change -6.4% -111.73%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 105.0K 290.0K
YoY Change -36.36% 7.81%
NET CHANGE
Cash From Operating Activities -28.16M -32.87M
Cash From Investing Activities 31.88M 24.50M
Cash From Financing Activities 105.0K 290.0K
Net Change In Cash 3.828M -8.080M
YoY Change -16.53% -93.29%
FREE CASH FLOW
Cash From Operating Activities -$28.16M -$32.87M
Capital Expenditures $398.0K $0.00
Free Cash Flow -$28.55M -$32.87M
YoY Change 2.28% -137.17%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Central Index Key
EntityCentralIndexKey
0001808158
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
A8
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
00-0000000
us-gaap Preferred Stock Shares Authorized Unlimited
PreferredStockSharesAuthorizedUnlimited
Unlimited
CY2022 us-gaap Preferred Stock Shares Authorized Unlimited
PreferredStockSharesAuthorizedUnlimited
Unlimited
us-gaap Common Stock Shares Authorized Unlimited
CommonStockSharesAuthorizedUnlimited
Unlimited
CY2022 us-gaap Common Stock Shares Authorized Unlimited
CommonStockSharesAuthorizedUnlimited
Unlimited
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-39335
dei Entity Registrant Name
EntityRegistrantName
Repare Therapeutics Inc.
dei Entity Address Address Line1
EntityAddressAddressLine1
7171 Frederick-Banting
dei Entity Address Address Line2
EntityAddressAddressLine2
Building 2
dei Entity Address Address Line3
EntityAddressAddressLine3
Suite 270
dei Entity Address City Or Town
EntityAddressCityOrTown
St-Laurent
dei Entity Address State Or Province
EntityAddressStateOrProvince
QC
dei Entity Address Country
EntityAddressCountry
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
H4S 1Z9
dei City Area Code
CityAreaCode
857
dei Local Phone Number
LocalPhoneNumber
412-7018
dei Security12b Title
Security12bTitle
Common shares, no par value
dei Trading Symbol
TradingSymbol
RPTX
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
42129651
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
107369000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
159521000
CY2023Q3 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
142703000
CY2022Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
184420000
CY2023Q3 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
15739000
CY2022Q4 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
0
CY2023Q3 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
3731000
CY2022Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
4323000
CY2023Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
5551000
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
5715000
CY2023Q3 us-gaap Assets Current
AssetsCurrent
275093000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
353979000
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4722000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4228000
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
3883000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
5371000
CY2023Q3 us-gaap Income Taxes Receivable Noncurrent
IncomeTaxesReceivableNoncurrent
2312000
CY2022Q4 us-gaap Income Taxes Receivable Noncurrent
IncomeTaxesReceivableNoncurrent
0
CY2023Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
397000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
497000
CY2023Q3 us-gaap Assets
Assets
286407000
CY2022Q4 us-gaap Assets
Assets
364075000
CY2023Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
5438000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
461000
CY2023Q3 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
20729000
CY2022Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
21645000
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2333000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2171000
CY2023Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
20472000
CY2022Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
53102000
CY2023Q3 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
0
CY2022Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
1240000
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
48972000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
78619000
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1591000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
3257000
CY2023Q3 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
2476000
CY2022Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
2682000
CY2023Q3 us-gaap Liabilities
Liabilities
53039000
CY2022Q4 us-gaap Liabilities
Liabilities
84558000
CY2023Q3 us-gaap Preferred Stock No Par Value
PreferredStockNoParValue
0
CY2022Q4 us-gaap Preferred Stock No Par Value
PreferredStockNoParValue
0
CY2023Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q3 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2023Q3 us-gaap Common Stock No Par Value
CommonStockNoParValue
0
CY2022Q4 us-gaap Common Stock No Par Value
CommonStockNoParValue
0
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
42129251
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
42129251
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
42036193
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
42036193
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
483184000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
482032000
CY2023Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
55515000
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
37226000
CY2023Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-252000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-428000
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-305079000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-239313000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
233368000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
279517000
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
286407000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
364075000
CY2023Q3 rptx Revenue From Collaboration Agreements
RevenueFromCollaborationAgreements
2159000
CY2022Q3 rptx Revenue From Collaboration Agreements
RevenueFromCollaborationAgreements
112545000
rptx Revenue From Collaboration Agreements
RevenueFromCollaborationAgreements
38086000
rptx Revenue From Collaboration Agreements
RevenueFromCollaborationAgreements
113632000
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
32709000
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
31242000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
98327000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
89175000
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7868000
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7904000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
25116000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
24621000
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
40577000
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
39146000
us-gaap Operating Expenses
OperatingExpenses
123443000
us-gaap Operating Expenses
OperatingExpenses
113796000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-38418000
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
73399000
us-gaap Operating Income Loss
OperatingIncomeLoss
-85357000
us-gaap Operating Income Loss
OperatingIncomeLoss
-164000
CY2023Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-40000
CY2022Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
126000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-137000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
250000
CY2023Q3 us-gaap Investment Income Net
InvestmentIncomeNet
3312000
CY2022Q3 us-gaap Investment Income Net
InvestmentIncomeNet
2027000
us-gaap Investment Income Net
InvestmentIncomeNet
10228000
us-gaap Investment Income Net
InvestmentIncomeNet
2700000
CY2023Q3 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
32000
CY2022Q3 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
37000
us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
73000
us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
56000
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
3240000
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2116000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
10018000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2894000
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-35178000
CY2022Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
75515000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-75339000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
2730000
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-16299000
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
54000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-9573000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
119000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-18879000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
75461000
us-gaap Net Income Loss
NetIncomeLoss
-65766000
us-gaap Net Income Loss
NetIncomeLoss
2611000
CY2023Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
172000
CY2022Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-524000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
176000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-524000
CY2023Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
172000
CY2022Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-524000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
176000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-524000
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-18707000
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
74937000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-65590000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
2087000
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.45
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.8
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.56
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.06
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.45
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.71
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.56
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.06
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
42102685
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
41945617
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
42077857
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
41902554
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
42102685
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
44177376
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
42077857
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
44160481
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
288421000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
28000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4755000
CY2022Q1 rptx Net Income Loss And Comprehensive Income Loss
NetIncomeLossAndComprehensiveIncomeLoss
-34757000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
258660000
CY2022Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
205000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4745000
CY2022Q2 rptx Net Income Loss And Comprehensive Income Loss
NetIncomeLossAndComprehensiveIncomeLoss
-38093000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
225517000
CY2022Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
50000
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5053000
CY2022Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-524000
CY2022Q3 us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
75461000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
305776000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
279517000
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
4000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6062000
CY2023Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
193000
CY2023Q1 us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
-34941000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
251244000
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
40000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6265000
CY2023Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-189000
CY2023Q2 us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
-11946000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
245414000
CY2023Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
4000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6377000
CY2023Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
172000
CY2023Q3 us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
-18879000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
233368000
us-gaap Profit Loss
ProfitLoss
-65766000
us-gaap Profit Loss
ProfitLoss
2611000
us-gaap Share Based Compensation
ShareBasedCompensation
18704000
us-gaap Share Based Compensation
ShareBasedCompensation
14553000
us-gaap Depreciation
Depreciation
1445000
us-gaap Depreciation
Depreciation
1523000
us-gaap Provision For Loan And Lease Losses
ProvisionForLoanAndLeaseLosses
1637000
us-gaap Provision For Loan And Lease Losses
ProvisionForLoanAndLeaseLosses
1643000
rptx Foreign Currency Transaction Gain Loss
ForeignCurrencyTransactionGainLoss
-71000
rptx Foreign Currency Transaction Gain Loss
ForeignCurrencyTransactionGainLoss
230000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
5809000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
733000
us-gaap Increase Decrease In Deferred Income Taxes
IncreaseDecreaseInDeferredIncomeTaxes
0
us-gaap Increase Decrease In Deferred Income Taxes
IncreaseDecreaseInDeferredIncomeTaxes
3857000
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-167000
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-676000
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
-559000
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
10797000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-100000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-89000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
4587000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
7066000
rptx Increase Decrease In Accrued Expenses And Other Current Liabilities
IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities
-916000
rptx Increase Decrease In Accrued Expenses And Other Current Liabilities
IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities
-1291000
rptx Increase Decrease In Operating Lease Liability Current
IncreaseDecreaseInOperatingLeaseLiabilityCurrent
117000
rptx Increase Decrease In Operating Lease Liability Current
IncreaseDecreaseInOperatingLeaseLiabilityCurrent
536000
us-gaap Increase Decrease In Income Taxes
IncreaseDecreaseInIncomeTaxes
-19291000
us-gaap Increase Decrease In Income Taxes
IncreaseDecreaseInIncomeTaxes
-1152000
rptx Increase Decrease In Operating Lease Liability Net
IncreaseDecreaseInOperatingLeaseLiabilityNet
-1771000
rptx Increase Decrease In Operating Lease Liability Net
IncreaseDecreaseInOperatingLeaseLiabilityNet
-1672000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-32836000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
20994000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-99002000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
29959000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1540000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2322000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
222000000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
6400000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
174298000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
213914000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
46162000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-209836000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
48000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
283000
rptx Proceeds From Issuance Of Common Stock Under Two Thousand Twenty Employee Share Purchase Plan
ProceedsFromIssuanceOfCommonStockUnderTwoThousandTwentyEmployeeSharePurchasePlan
689000
rptx Proceeds From Issuance Of Common Stock Under Two Thousand Twenty Employee Share Purchase Plan
ProceedsFromIssuanceOfCommonStockUnderTwoThousandTwentyEmployeeSharePurchasePlan
432000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
737000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
715000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-49000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-74000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-52152000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-179236000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
159521000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
334427000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
107369000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
155191000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
399000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
0
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
149000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
56000
dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2016-09-06
CY2023Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y8M12D
CY2022Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y8M1D
CY2023Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.041
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Use of Estimates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in consolidated financial statements and accompanying notes. Significant estimates and assumptions reflected in these unaudited condensed consolidated financial statements include, but are not limited to, estimates related to revenue recognition, accrued research and development expenses, share-based compensation, right-of-use assets and lease liabilities and income taxes. The Company bases its estimates on historical experience and other market specific or other relevant assumptions that it believes to be reasonable under the circumstances. Actual results could differ from those estimates. Changes in estimates are recorded in the period in which they become known.</span></p>
CY2023Q3 us-gaap Accrued Investment Income Receivable
AccruedInvestmentIncomeReceivable
300000
CY2022Q4 us-gaap Accrued Investment Income Receivable
AccruedInvestmentIncomeReceivable
400000
CY2023Q3 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
142700000
CY2022Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
157900000
CY2023Q3 us-gaap Debt Securities Available For Sale Allowance For Credit Loss Not Previously Recorded
DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded
0
CY2022Q3 us-gaap Debt Securities Available For Sale Allowance For Credit Loss Not Previously Recorded
DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded
0
us-gaap Debt Securities Available For Sale Allowance For Credit Loss Not Previously Recorded
DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded
0
us-gaap Debt Securities Available For Sale Allowance For Credit Loss Not Previously Recorded
DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded
0
CY2023Q3 us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
200000
us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
200000
CY2022Q3 us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
-500000
us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
-500000
CY2023Q3 rptx Fair Value Assets Transfers Between All Levels
FairValueAssetsTransfersBetweenAllLevels
0
CY2023Q3 us-gaap Income Tax Receivable
IncomeTaxReceivable
18100000
CY2023Q3 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
15700000
CY2023Q3 us-gaap Income Taxes Receivable Noncurrent
IncomeTaxesReceivableNoncurrent
2300000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
56000
CY2023Q3 rptx Research And Development Tax Credits Receivable
ResearchAndDevelopmentTaxCreditsReceivable
2328000
CY2022Q4 rptx Research And Development Tax Credits Receivable
ResearchAndDevelopmentTaxCreditsReceivable
1280000
CY2023Q3 us-gaap Receivables Long Term Contracts Or Programs
ReceivablesLongTermContractsOrPrograms
0
CY2022Q4 us-gaap Receivables Long Term Contracts Or Programs
ReceivablesLongTermContractsOrPrograms
1525000
CY2023Q3 rptx Other Receivables Net Current Other
OtherReceivablesNetCurrentOther
1403000
CY2022Q4 rptx Other Receivables Net Current Other
OtherReceivablesNetCurrentOther
1518000
CY2023Q3 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
3731000
CY2022Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
4323000
CY2023Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
5105000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
5616000
CY2023Q3 rptx Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
15013000
CY2022Q4 rptx Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
15078000
CY2023Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
508000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
680000
CY2023Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
103000
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
271000
CY2023Q3 rptx Accrued Expenses And Other Liabilities Current
AccruedExpensesAndOtherLiabilitiesCurrent
20729000
CY2022Q4 rptx Accrued Expenses And Other Liabilities Current
AccruedExpensesAndOtherLiabilitiesCurrent
21645000
CY2023Q3 rptx Revenue From Collaboration Agreements
RevenueFromCollaborationAgreements
2159000
CY2022Q3 rptx Revenue From Collaboration Agreements
RevenueFromCollaborationAgreements
112545000
rptx Revenue From Collaboration Agreements
RevenueFromCollaborationAgreements
38086000
rptx Revenue From Collaboration Agreements
RevenueFromCollaborationAgreements
113632000
rptx Number Of Operating Leases
NumberOfOperatingLeases
4
us-gaap Lessee Operating Lease Existence Of Option To Terminate
LesseeOperatingLeaseExistenceOfOptionToTerminate
false
CY2023Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
593000
CY2022Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
614000
us-gaap Operating Lease Cost
OperatingLeaseCost
1779000
us-gaap Operating Lease Cost
OperatingLeaseCost
1845000
CY2023Q3 us-gaap Short Term Lease Cost
ShortTermLeaseCost
39000
CY2022Q3 us-gaap Short Term Lease Cost
ShortTermLeaseCost
9000
us-gaap Short Term Lease Cost
ShortTermLeaseCost
86000
us-gaap Short Term Lease Cost
ShortTermLeaseCost
24000
CY2023Q3 us-gaap Variable Lease Cost
VariableLeaseCost
86000
CY2022Q3 us-gaap Variable Lease Cost
VariableLeaseCost
32000
us-gaap Variable Lease Cost
VariableLeaseCost
186000
us-gaap Variable Lease Cost
VariableLeaseCost
132000
CY2023Q3 us-gaap Lease Cost
LeaseCost
718000
CY2022Q3 us-gaap Lease Cost
LeaseCost
655000
us-gaap Lease Cost
LeaseCost
2051000
us-gaap Lease Cost
LeaseCost
2001000
us-gaap Operating Lease Payments
OperatingLeasePayments
1799000
us-gaap Operating Lease Payments
OperatingLeasePayments
1334000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
149000
CY2022Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.04
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
8032902
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
14.38
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2306940
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
11.73
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
17450
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
2.65
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
234801
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
14.99
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
10087591
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
13.78
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
17450
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
2.65
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
7.77
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
8.45
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
8.31
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
9.4
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0436
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0289
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0371
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0209
CY2023Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y29D
CY2022Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y29D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y3D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y11M23D
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.8173
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.812
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.8149
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.7882
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6377000
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5053000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
18704000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
14553000
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6377000
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5053000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
18704000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
14553000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-18879000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
75461000
us-gaap Net Income Loss
NetIncomeLoss
-65766000
us-gaap Net Income Loss
NetIncomeLoss
2611000
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
42102685
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
41945617
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
42077857
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
41902554
CY2023Q3 rptx Incremental Common Shares Attributable To Dilutive Effect Of Stock Options And Shares Issuable Under The Espp
IncrementalCommonSharesAttributableToDilutiveEffectOfStockOptionsAndSharesIssuableUnderTheEspp
0
CY2022Q3 rptx Incremental Common Shares Attributable To Dilutive Effect Of Stock Options And Shares Issuable Under The Espp
IncrementalCommonSharesAttributableToDilutiveEffectOfStockOptionsAndSharesIssuableUnderTheEspp
2231759
rptx Incremental Common Shares Attributable To Dilutive Effect Of Stock Options And Shares Issuable Under The Espp
IncrementalCommonSharesAttributableToDilutiveEffectOfStockOptionsAndSharesIssuableUnderTheEspp
0
rptx Incremental Common Shares Attributable To Dilutive Effect Of Stock Options And Shares Issuable Under The Espp
IncrementalCommonSharesAttributableToDilutiveEffectOfStockOptionsAndSharesIssuableUnderTheEspp
2257927
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
42102685
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
44177376
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
42077857
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
44160481
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.45
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.8
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.56
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.06
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.45
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.71
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.56
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.06

Files In Submission

Name View Source Status
0000950170-23-061521-index-headers.html Edgar Link pending
0000950170-23-061521-index.html Edgar Link pending
0000950170-23-061521.txt Edgar Link pending
0000950170-23-061521-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
rptx-20230930.htm Edgar Link pending
rptx-20230930.xsd Edgar Link pending
rptx-ex31_1.htm Edgar Link pending
rptx-ex31_2.htm Edgar Link pending
rptx-ex32_1.htm Edgar Link pending
rptx-ex32_2.htm Edgar Link pending
Show.js Edgar Link pending
rptx-20230930_pre.xml Edgar Link unprocessable
rptx-20230930_htm.xml Edgar Link completed
rptx-20230930_def.xml Edgar Link unprocessable
rptx-20230930_cal.xml Edgar Link unprocessable
rptx-20230930_lab.xml Edgar Link unprocessable